Hologic agrees to $18.3 billion take-private deal, shareholders to receive cash and CVR on the stock

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-26, 11:57.

Hologic (US4364401012) has agreed to be taken private by a consortium led by Blackstone and TPG in a transaction valued at about $18.3 billion including debt, according to Reuters’ deal reporting and legal industry coverage, with its shares currently listed on NASDAQ. The consortium will acquire all outstanding Hologic shares at $76 per share in cash plus a contingent value right of up to $3 per share tied to Breast Health revenue milestones, implying total potential consideration of up to $79 per share.

What the take-private deal includes

The Blackstone- and TPG-led group will pay $76 in cash for each Hologic share, representing a premium of nearly 6 percent to the stock’s last closing price before the agreement was announced, as highlighted in Reuters-based summaries of the deal. In addition to the cash component, shareholders are set to receive a non-tradable contingent value right worth up to $3 per share if specific global revenue targets are met in Hologic’s Breast Health business during fiscal years 2026 and 2027.

Legal reporting describes the transaction value at approximately $18.3 billion including debt, characterizing it as one of the largest medical devices deals in almost two decades. Law firms including Wachtell Lipton Rosen & Katz are advising Hologic, while Kirkland & Ellis and Ropes & Gray are working with the private equity consortium on corporate and healthcare-regulatory aspects of the deal, underlining the scale and complexity of the planned NASDAQ-listed company buyout.

How analysts and peers frame Hologic

Before the take-private announcement, Hologic carried a consensus rating of Hold on MarketBeat, with an average analyst price target around $79.09, a high estimate of $90 and a low of $70, implying modest upside from recent trading levels. The same data set indicates a market capitalization near $17 billion and a price-to-earnings ratio in the low-30s, placing Hologic among established mid- to large-cap U.S. medical technology names.

In the broader medtech and diagnostics space, Hologic competes with groups such as Siemens Healthineers in breast imaging and diagnostics and with players like Becton Dickinson and Abbott in women’s health and diagnostics niches, although business mixes differ across these peers. Hologic’s reported 52-week trading range from about $51.90 to slightly above $76.00 highlights how the $76 per share cash offer and potential CVR value align with levels tested near the upper end of its recent NASDAQ trading band.

The business behind the take-private

Hologic positions itself as a global leader in women’s health, with business lines spanning breast and skeletal health, diagnostic solutions and gynecological surgical products, as reiterated in the company’s 2025 Sustainability Report release. The report, published in June 2026 to mark Hologic’s 40th anniversary, emphasizes the company’s mission of enabling healthier lives for women worldwide and documents progress on environmental, social and governance initiatives across its operations.

Within imaging and diagnostics, Hologic’s Breast Health segment manufactures mammography systems and related technologies used in breast cancer screening and diagnosis, a portfolio that sits at the core of the CVR structure in the Blackstone- and TPG-led offer. Additionally, the company develops molecular diagnostic assays and instruments widely used for cervical cancer screening and sexually transmitted infection testing, complementing its imaging franchise and providing recurring revenue from consumables and services.

Where the stock trades today

Hologic shares (US4364401012) most recently traded on NASDAQ around the mid-70s in U.S. dollars, close to the $76 per share cash consideration offered in the announced take-private transaction, with the precise last price and intraday range available on live quote services. The shares remain part of the U.S. healthcare and medical technology universe tracked by major indices and sector benchmarks, pending completion of the Blackstone- and TPG-led acquisition.

This article is for informational purposes only and does not constitute investment advice, investment recommendation or an offer or solicitation to buy or sell any financial instruments. Figures and assessments are based on sources cited and may change over time.